Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -123,22 +123,34 @@
123	123
124	124	The Company changed its segment structure. The new segment structure resulted in a change to the Company’s former Ortho Dermatologics segment whereby its medical dermatology business (Ortho Dermatologics) is now managed by the Chief Operating Decision Maker (“CODM”) as part of the Diversified Products segment and the Solta Medical business is now managed by the CODM as its own operating and reportable segment.
125	125
126		-Separation of the Bausch + Lomb Eye Health Business
127	127
	127	+**Separation of the Bausch + Lomb Eye Health Business**
	128	+
	129	+
128	128	The company announced its plan to separate its eye health business consisting of its Bausch + Lomb Global Vision Care (formerly Vision Care/Consumer Health), Global Surgical and Global Ophthalmic Pharmaceuticals businesses into an independent publicly traded entity, Bausch + Lomb from the remainder of Bausch Health Companies Inc. (the “B+L Separation”). In January 2022, the company completed the internal organizational design and structure of the new eye health entity.
129	129
130		-Solta Medical
131	131
	133	+**Solta Medical**
	134	+
132	132	The Company announced it was suspending its previously announced plans to pursue an IPO of its Solta aesthetic medical device business.
133	133
134		-R&D Investment
135	135
	138	+== R&D Investment ==
	139	+
136	136	The company's internal R&D organization focuses on the development of products through clinical trials. As of December 31, 2021, approximately 1,300 dedicated R&D and quality assurance employees in 25 R&D facilities were involved in its R&D efforts internally.
137	137
	142	+
138	138	As of June 30, 2022, Bausch Health has approximately 160 projects in its global pipeline.
139	139
140		-Pipeline
141	141
142		-<pipe img>
	146	+=== Pipeline ===
143	143
	148	+
	149	+[[image:BHC3.png]]
	150	+
	151	+
	152	+= References =
	153	+
	154	+
	155	+
144	144	{{putFootnotes/}}